X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14686) 14686
Publication (1082) 1082
Book Review (168) 168
Book Chapter (92) 92
Book / eBook (40) 40
Conference Proceeding (17) 17
Magazine Article (11) 11
Dissertation (10) 10
Newsletter (5) 5
Data Set (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9842) 9842
index medicus (7553) 7553
male (6476) 6476
female (6068) 6068
middle aged (4181) 4181
animals (3687) 3687
adult (3442) 3442
aged (3261) 3261
risk factors (1893) 1893
serum (1846) 1846
albumin (1808) 1808
analysis (1746) 1746
mortality (1591) 1591
serum albumin - metabolism (1495) 1495
pharmacology & pharmacy (1430) 1430
serum albumin - analysis (1430) 1430
proteins (1418) 1418
urology & nephrology (1407) 1407
serum albumin (1332) 1332
rats (1218) 1218
treatment outcome (1096) 1096
health aspects (1068) 1068
aged, 80 and over (1034) 1034
time factors (1016) 1016
research (1014) 1014
biomarkers - blood (1002) 1002
inflammation (999) 999
prospective studies (985) 985
mice (943) 943
oxidative stress (916) 916
retrospective studies (906) 906
prognosis (903) 903
serum-albumin (902) 902
biochemistry & molecular biology (882) 882
care and treatment (864) 864
adolescent (840) 840
medicine & public health (816) 816
toxicology (815) 815
surgery (803) 803
disease (800) 800
risk (761) 761
endocrinology & metabolism (756) 756
medicine (741) 741
cancer (728) 728
liver (710) 710
nutrition & dietetics (703) 703
patients (696) 696
article (690) 690
physiological aspects (688) 688
immunology (669) 669
oncology (656) 656
research article (642) 642
young adult (636) 636
cattle (633) 633
diabetes (630) 630
metabolism (629) 629
hemodialysis (627) 627
nephrology (596) 596
therapy (590) 590
medical research (589) 589
protein (588) 588
biomarkers (587) 587
protein binding (581) 581
studies (568) 568
follow-up studies (565) 565
survival (558) 558
kidney failure, chronic - therapy (556) 556
toxicity (556) 556
in-vitro (555) 555
renal dialysis - adverse effects (544) 544
c-reactive protein (541) 541
creatinine - blood (540) 540
gastroenterology & hepatology (536) 536
nutritional status (534) 534
multidisciplinary sciences (524) 524
hematology (521) 521
blood (518) 518
kidney diseases (512) 512
dose-response relationship, drug (506) 506
nutrition (501) 501
serum creatinine (499) 499
transplantation (498) 498
body mass index (493) 493
child (488) 488
chronic kidney-disease (488) 488
medicine, general & internal (481) 481
plasma (481) 481
nanoparticles (474) 474
human serum-albumin (473) 473
medicine, research & experimental (464) 464
pregnancy (462) 462
glomerular filtration rate (459) 459
internal medicine (457) 457
cholesterol (454) 454
prevalence (452) 452
cross-sectional studies (451) 451
multivariate analysis (448) 448
diagnosis (447) 447
medicine, experimental (446) 446
expression (438) 438
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (36) 36
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Online Resources - Online (3) 3
UofT at Scarborough - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Mt Sinai Hospital - Pathology (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14497) 14497
German (98) 98
Japanese (36) 36
Chinese (30) 30
French (30) 30
Spanish (30) 30
Russian (24) 24
Polish (19) 19
Italian (9) 9
Danish (7) 7
Portuguese (7) 7
Dutch (4) 4
Arabic (3) 3
Czech (3) 3
Hebrew (3) 3
Swedish (3) 3
Bulgarian (2) 2
Hungarian (2) 2
Turkish (2) 2
Croatian (1) 1
Greek (1) 1
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Stroke, ISSN 0039-2499, 09/2016, Volume 47, Issue 9, pp. 2355 - 2359
BACKGROUND AND PURPOSE—The ALIAS (Albumin in Acute Ischemic Stroke) part 1 and 2 trials evaluated whether 25% human serum albumin improves clinical outcomes... 
risk | acute stroke | serum albumin | randomized trial | albumin | DESIGN | MULTICENTER CLINICAL-TRIAL | THERAPY | MARKED NEUROPROTECTIVE EFFICACY | SAFETY | PERIPHERAL VASCULAR DISEASE | CLINICAL NEUROLOGY | Albumins - therapeutic use | Treatment Outcome | Stroke - drug therapy | Albumins - adverse effects | Brain Ischemia - drug therapy | Humans
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2/2015, Volume 23, Issue 2, pp. 525 - 545
Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte colony-stimulating factors (G-CSFs) have recently been developed. We... 
Pain Medicine | Pegfilgrastim | Nursing | Rehabilitation Medicine | Medicine & Public Health | Granulocyte colony-stimulating factor | Lipegfilgrastim | Oncology | Systematic review | Balugrastim | Nursing Management/Nursing Research | Neutropenia | SINGLE-ADMINISTRATION PEGFILGRASTIM | PHASE-II | LYMPHOMA PATIENTS | DOSE INTENSITY | BREAST-CANCER | ONCOLOGY | ALBUMIN-BOUND PACLITAXEL | FEBRILE NEUTROPENIA | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PATIENTS RECEIVING CHEMOTHERAPY | DAILY FILGRASTIM | DARBEPOETIN-ALPHA | Granulocyte Colony-Stimulating Factor - adverse effects | Recombinant Proteins - therapeutic use | Polyethylene Glycols | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Chemotherapy-Induced Febrile Neutropenia - prevention & control | Antineoplastic Agents - therapeutic use | Recombinant Proteins - adverse effects | Granulocyte Colony-Stimulating Factor - therapeutic use | Filgrastim | Serum Albumin, Human | Neoplasms - drug therapy | Serum Albumin - adverse effects | Serum Albumin - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Chemotherapy-Induced Febrile Neutropenia - drug therapy | Female | Taxoids - adverse effects | Political activity | Cancer patients | Chemotherapy | Drug therapy | Political aspects | Cancer | Effectiveness
Journal Article
Trials, ISSN 1745-6215, 08/2015, Volume 16, Issue 1, p. 384
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 01/2016, Volume 21, Issue 1, pp. 7 - 15
Objectives. This study aimed to evaluate the efficacy and safety of once‐per‐cycle balugrastim versus pegfilgrastim for neutrophil support in breast cancer... 
Pegfilgrastim | Balugrastim | Breast cancer | Myelosuppressive therapy | Granulocyte colony‐stimulating factor | MULTICENTER | COLONY-STIMULATING FACTORS | MANAGEMENT | SINGLE-ADMINISTRATION PEGFILGRASTIM | Granulocyte colony | stimulating factor | CLINICAL-PRACTICE GUIDELINES | ONCOLOGY | RECOMMENDATIONS | FEBRILE NEUTROPENIA | UPDATE | DAILY FILGRASTIM | CYCLE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Serum Albumin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Recombinant Proteins - adverse effects | Filgrastim | Serum Albumin, Human | Drug-Related Side Effects and Adverse Reactions - pathology | Serum Albumin - adverse effects | Dose-Response Relationship, Drug | Adult | Female | Recombinant Fusion Proteins - administration & dosage | Taxoids - adverse effects | Doxorubicin - administration & dosage | Neutrophils - pathology | Granulocyte Colony-Stimulating Factor - adverse effects | Polyethylene Glycols | Neutrophils - drug effects | Breast Neoplasms - drug therapy | Recombinant Proteins - administration & dosage | Blood Cell Count | Taxoids - administration & dosage | Breast Neoplasms - pathology | Drug-Related Side Effects and Adverse Reactions - drug therapy | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Academia-Pharma Intersect | Granulocyte colony-stimulating factor | Breast Cancer
Journal Article